Poletti Samuel Jonas purchased $118K of AMRZ

Poletti Samuel Jonas (Chief Strategy & M&A Officer) purchased 2,510 shares of Amrize Ltd (AMRZ) at $46.92 ($0.12M total) on 2026-08-17.

Original reporting
SEC EDGAR · Poletti Samuel Jonas
Published Aug 18, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 4:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMRZ
Bullish
low confidence
Mentioned
$AMRZ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishLow
01

Why it matters

The newest fact is the specific open-market purchase size, price, and post-transaction holdings by the company’s Chief Strategy and M&A Officer.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no accompanying operational or financial update.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not provide the insider’s rationale or whether the purchase is part of a broader pattern.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Amrize Ltd (AMRZ).

Company-level read

Ticker impact

$AMRZBullishLow confidence
Context

Amrize Ltd insider Poletti Samuel Jonas bought 2,510 shares at $46.9200 on 2026-08-17, totaling $117,769.20.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys are informational but typically do not change earnings, guidance, or capital structure; the filing provides no new company-specific operational or financial development.

Market effects

No sector-level signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-planned behavior) and may not reflect a change in outlook.

Key entities

  • Amrize Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Poletti Samuel Jonas

    Chief Strategy and M&A Officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.